recruitment of polymorphonuclear cells, platelets 7 , IL-17 producing T cells, 8 and other effectors of inflammation. While complement inhibition using various inhibitors appears to mitigate IRI in many animal models 3 , it has been wisely entertained that generalized complement inhibition may increase the risk of infections and this may be catastrophic in conditions like intestinal IRI when the entry of pathogens in to the blood stream may become uncontrolled. To this end the Hollers lab has considered "targeted" delivery of complement inhibitors to "hush" complement activation only at the site of injury. At the site of injury, C3 is broken down to generate iC3b and C3dg which can be found deposited locally. iC3b and C3dg represent ligands for complement receptor 2 (CR2) and when the iC3b/C3dg binding component of CR2 was conjugated to a mouse complement-inhibitory protein (Crry), Crry was delivered only to the injured areas and IRI ceased 9 .
In the accompanying article in this issue of Circulation, Atkinson et al 10 found annexin IV to be expressed on transplanted hearts in mice. They constructed an anti-annexin IV single chain antibody (scFv) and conjugated it to Crry. scFv-Crry targeted the transplanted hearts, limited complement deposition to the graft and inflammation. As predicted 9 , immunity to infection was not affected and therefore, repeated or prolonged administration of such a targeted complement inhibitor should not be associated with generalized immunosuppression. Organ transplantation, revascularization surgery, vasculitis and other conditions should be expected to benefit from this approach. It has been mentioned already that complement activation and pathways leading to IRI may not be identical in all organs and the expression of neoantigens may I In In t t the he he acc cc co om ompanying article in this issue e o o of C Circulation, At At Atkins nson on on et al 10 found annexin V V t t to o be expre ess ssed ed ed o on n tr ran an ansp sp spla la lant nted ed d h h hea ea art t ts in n m m mice. . T T They ey ey c con on ns st tru ruc c cte ed ed a an n n a an nti ti-a -a -ann nnex ex xin in n I IV V V si si sing ng gle e e ch h hai ai ain n n an an a ti tibo bo body d dy ( ( (s sc scFv Fv F ) ) ) an an nd d co o onj nj n ug ug uga a ate te ted d i it i t t to o o C C Crry ry ry. s sc cF Fv v-v-Cr Cr Crry ry ry t tar ar arg g et et e ed ed ed t th h he t tra ran ns nspl pl plan an nte te ted d h h hea ar arts ts, , , imited comp mp ple le leme me ment nt nt d d dep ep epos sit it itio io ion to to to t the he h g g gr r raf af aft t t an an and d d in in nfl fl flam am amma ma mati ti tion on on. As As As p p pre re redi di d ct ct cted ed ed 9 9 9 , , im im immu mu muni ni n ty to and if deleted genetically, the kidney suffers extensive IRI 11, 12 . As more kidney transplants (~17,000 each year) than heart transplants (2,000 each year) are performed in the US, it would be interesting to know whether annexin IV is similarly expressed in the transplanted kidney and whether scFv-Crry would have a similar protective effect. Certainly, Crry being is been lost in the kidney during IRI and its replacement is needed but the targeting carrier should be identified.
That complement activation is rampant in kidney transplants and many types of nephritides have been demonstrated in multiple complement-deficient mice (for example C3 deficiency mitigates injury whereas lack of complement regulators worsens injury) and various complement inhibitors avert damage invariably 13 . Atkinson et al 10 though prompt us to consider targeted delivery of complement inhibitors, and the best approach for the kidney as well as for other molecules needs to be defined.
The nucleotide-binding oligomerization domain (NOD) proteins NOD1 and NOD2, the first members of the intracellular NOD-like receptor family, sense conserved motifs in bacterial peptidoglycan present on the cell wall of bacteria and induce proinflammatory and antimicrobial responses. NOD1 and NOD2, unlike Toll-like receptors which recognize microbial ligands at the cell surface or within endosomes, sense bacterial products in the host cytosol 14 . They are also important in the expression of kidney IRI, 15 and antibiotic treatment limits intestinal IRI 16 . But it appears that NODs can be activated not only in the presence of bacteria but also by peptidoglycan present in antigen present cells in the CNS 17 and possibly elsewhere. reperfusion, involves a number of other pathways, which should be reconsidered in the context of NOD2 engagement. Platelets from CD40 or CD40 ligand deficient mice cannot lodge in remote (lung) tissues and cause damage 19 while spleen tyrosine kinase (Syk) appears to be necessary for platelet-executed remote organ damage 20 and platelet factor 4 deficient mice do RI, platelets lodge at increasing amounts over 24 hours in the lungs and they app pp pea a ar r to to to b b be e e covered with complement 7 r . While we do not know if complement deposition causes or fa aci ci ili li lita ta tate te tes s pl pl plat at a el let et et a a act c ivation, it is certain that the e e de de eposited comp ple le l me ent nt nt m may facilitate remote o odg g gin i g wherea eas s p pe ept ptid id i o og ogl ly lyca ca can n n ac ac cti ti tiv va vat t tes s them em em and d c cau us use es es t t thr hr rom om mbu bu us s fo fo f rm rm rmat ati i ion on n. . In In In t t tha ha h t re re resp sp pec ec ct, h he e e sc sc cFv Fv F -C -C Crr rr rry y y co co ons s str truc uct t pr pr p ev even en e ts ts ts c c com o omp pl plem em emen e ent t ac ac a t ti iv v a atio io on n n at at at t the he he s si i ite e e of of o i i inj njur ur u y y y an an nd d by by by not ot t a a alt lter er rin ing g g mmunity to ba ba bact ct c er er eria ia ia, , li li l mi m m ts ts ts th th the e po po poss ss ssib ibil il ilit it ty y y fo fo for r r MD MD MDP-P-P me me edi di diat at a ed ed ed p p pla la l te e ele le let t t ac ac acti ti tiva va v ti i ion on on. . not suffer local (intestinal) or remote (lung) injury 21 . It would be interesting to know whether MDP can cause platelet aggregation in the absence of CD40, CD40 ligand, Syk, or platelet factor 4 deficiency as in the absence of MAPK. The value of this information lies with the possibility of expanding the list of drugs which can limit tissue damage facilitated by activated platelets.
Platelets have been assigned additional roles besides thrombus formation and hemostasis.
When activated they produce a number of inflammatory molecules including IL-1beta which promote inflammation where they happen to lodge 22 . Zhang et al 18 show here that platelets stimulated thorough NOD2 produce IL-1beta indicating that even this mode of stimulation bestows on to platelets inflammatory capacity.
Platelets have more recently been identified to be important in the pathogenesis of autoimmune diseases like rheumatoid arthritis. When activated they release microparticles which are abundant in the synovial fluid, release IL-1 which in turn stimulates proliferation of synovial fibroblasts 23 and the development of arthritis. In patients with systemic lupus erythematosus and lupus-prone mice, platelets are activated and express on the surface CD40 ligand through which they serve a strong costimulatory signal to B cells to produce autoantibody 24 .
The two accompanying papers 10, 18 address two important points in the current practice of medicine (Figure 1) . Complement becomes activated in transplanted organs and many other clinical conditions where there is an element of ischemia followed by reperfusion. Platelets traveling through the burning land will become decorated by complement proteins, become activated by peptidoglycan available either by surrounding bacteria or antigen presenting cells (possibly other cells) and probably by thrombin and collagen and then travel to other places where they will attach to the walls of vessels and initiate thromboembolism or lodge in the Platelets have more recently been identified f f f to be important in the pathog ge ene ne esi i is s of of of autoimmune diseases like rheumatoid arthritis. When activated they release microparticles wh whic ic ich h h a ar are e ab ab abu u unda da an nt nt in the synovial fluid, release e e I IL L L-1 which in tur ur rn f sti ti imu m mulates proliferation of y yno o novial fibro obl bl la a ast t ts 23 23 23 and nd nd t t the he he d dev ev vel el lop opm m ment of f f art th hr r ritis s. s. In In n p pat atie ie en nt ts wi wi with h s sys ys yste te emi mic c c lu lu lupu pu us er ryt yt ythe he hema ma m to to osu su sus s an an nd d d lu lup pu pus-s-s p pron on one e mi mi mice c ce, , p pl plat at atel el ele e ets s s ar ar a e e e a ac acti ti iva va ate te ted d d an an and d ex ex xpr pr pres es ss on on t t the he e s sur ur urf fa face e e C C CD4 D4 40 0 igand through gh gh w w whi hi hich ch c t t the he h y y se se serv rv r e e e a a a st st stro r ng ng ng c c cos os osti ti timu mu mula la ato to ory ry s s si ign gn gnal al al t t to o o B ce ce cell ll lls s s to to to p p pro ro odu du duce ce ce microvasculature of organs such as the lung and the CNS and compromise their function. In both places they will release IL-1 and instigate inflammation or modulate the immune system otherwise. It seems that targeted inhibition of complement activation, which is expected to limit bacterial infections and platelet activation, will result in limited local organ damage and remote organ damage will be avoided.
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